Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.69 |
| ▸ | SHBG | P04278 | 2/20 | 0.60 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.60 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.48 |
| ▸ | PGR | P06401 | 4/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9799432 | 1.00 | AR (0.69) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL24102603 | 0.87 | AR (0.74) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL6241583 | 0.87 | AR (0.74) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL24102607 | 0.87 | AR (0.74) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL6836662 | 0.87 | AR (0.74) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL6841921 | 0.87 | AR (0.74) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL5026470 | 0.86 | AR (0.72) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL16875673 | 0.86 | AR (0.72) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL17302821 | 0.86 | AR (0.72) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL6836638 | 0.85 | AR (0.71) | ARSHBGSERPINA6SLC22A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | AKZO NOBEL N.V. (NL) | 2004-10-21 | — | — | US | disclosed |
| US-6780854-B2 | MALE CONTRACEPTION | AKZO NOBEL NV (NL) | 2004-08-24 | — | — | US | disclosed |
| US-6756366-B1 | 19-NORTESTOSTERONE DERIVATIVES; ORALLY ACTIVE; HIGH POTENCY | AKZO NOBEL N.V. (NL) | 2004-06-29 | — | — | US | disclosed |
| EP-1203011-B1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL NV (NL) | 2004-01-02 | — | — | EP | disclosed |
| EP-1212345-B1 | ORALLY ACTIVE 7-ALPHA-ALKYL ANDROGENS | AKZO NOBEL NV (NL) | 2003-08-06 | — | — | EP | disclosed |
| US-20030087886-A1 | Orally active androgens | LOOZEN HUBERT JAN JOZEF (NL) | 2003-05-08 | — | — | US | disclosed |
| US-6541465-B2 | Delta 14 derivatives of 19- nortestosterone, useful for the preparation of a medicine for treating androgen insufficiency | AKZO NOBEL N.V. (NL) | 2003-04-01 | — | — | US | disclosed |
| EP-1212345-A2 | ORALLY ACTIVE 7.ALPHA.-ALKYL ANDROGENS | Akzo Nobel N.V. (NL) | 2002-06-12 | — | — | EP | disclosed |
| EP-1203011-A1 | ORALLY ACTIVE ANDROGENS | Akzo Nobel N.V. (NL) | 2002-05-08 | — | — | EP | disclosed |
| US-20020022609-A1 | Orally active androgens | LOOZEN HUBERT JAN JOZEF (NL) | 2002-02-21 | — | — | US | disclosed |
| US-6313108-B1 | TREATING ANDROGEN INSUFFICIENCY | AKZO NOBEL N.V. (NL) | 2001-11-06 | — | — | US | disclosed |
| WO-2001005806-A1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL N.V. (NL) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000059920-A2 | ORALLY ACTIVE 7.ALPHA.-ALKYL ANDROGENS | AKZO NOBEL N.V. (NL) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087886-A1 | Orally active androgens | NR5A1, AR, CYP17A1 | AR 2/4885SHBG 8/4885SERPINA6 268/4885 |
| US-20020022609-A1 | Orally active androgens | NR5A1, AR, CYP17A1 | AR 2/4885SHBG 8/4885SERPINA6 274/4885 |
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | NR5A1, AR, SHBG | AR 2/4885SHBG 3/4885SERPINA6 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.